Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Luis Abegão Pinto, EGS 2020 – Programme Highlights and Reflections on 2020 (Part 1)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 5th 2021

We were delighted to speak with our esteemed Editorial Board member, Luis Abegão Pinto (Lisbon University, Lisbon, Portugal) about the impact of the COVID-19 pandemic on management of patients with glaucoma, the challenges of organising a virtual conference and the highlights of the EGS 2020 programme.

Questions

  1. How has the COVID-19 pandemic impacted on the management of patients with glaucoma? (00:44)
  2. What have been the challenges and opportunities of organising a virtual conference this year? (02:35)
  3. What have we learned in 2020 about the best ways to navigate this new virtual conference world? (04:58)

Speaker Disclosure: Dr Luis Abegão Pinto has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of EGS 2020.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup